NCT03952325 - Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | Biotech Hunter

Enrollment

294

Participants

Timeline

Start Date

July 9, 2019

Primary Completion Date

June 23, 2021

Study Completion Date

June 23, 2021

Conditions

Breast Cancer

Interventions

DRUG

Tesetaxel

Tesetaxel at 27 mg/m2 orally Q3W

DRUG

Tesetaxel

Tesetaxel at 27 mg/m2 orally Q3W

DRUG

Tesetaxel

Tesetaxel at 27 mg/m2 orally Q3W

DRUG

Nivolumab

Nivolumab at 360 mg by intravenous infusion Q3W

DRUG

Pembrolizumab

Pembrolizumab at 200 mg by intravenous infusion Q3W

DRUG

Atezolizumab

Atezolizumab at 1,200 mg by intravenous infusion Q3W

DRUG

Tesetaxel

Tesetaxel at 27 mg/m2 orally Q3W

Trial Locations (12)

11733

New York Cancer and Blood Specialists, East Setauket

23502

Virginia Oncology Associates, Norfolk

32308

Florida Cancer Specialists and Research Institute - Panhandle Region, Tallahassee

33401

Florida Cancer Specialists and Research Institute, West Palm Beach

33705

Florida Cancer Specialists and Research Institute, St. Petersburg

33901

Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers

38138

West Cancer Center, Germantown

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

02215

Dana-Farber Cancer Institute, Boston

Unknown

John Hopkins Singapore International Medical Centre, Singapore

National Cancer Centre Singapore, Singapore

Asan Medical Center, Seoul